Bacterial composition and its use

Abstract

The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

1. A bacterial composition having immunomodulation properties comprising  Bifidobacterium lactis  PTA-4802. 
     
     
       2. The bacterial composition according to  claim 1  further comprising at least one additional strain selected from the group consisting of  Lactobacillus acidophilus  PTA-4797,  Lactobacillus plantarum  PTA-4799,  Lactobacillus salivarius  PTA-4800,  Lactobacillus paracasei  PTA-4798, and  Bifidobacterium bifidum  PTA-4801. 
     
     
       3. The bacterial composition according to  claim 1  further comprising at least two additional strains selected from the group consisting of  Lactobacillus acidophilus  PTA-4797,  Lactobacillus plantarum  PTA-4799,  Lactobacillus salivarius  PTA-4800,  Lactobacillus paracasei  PTA-4798, and  Bifidobacterium bifidum  PTA-4801. 
     
     
       4. The bacterial composition according to  claim 1  comprising a blend of  Lactobacillus acidophilus  PTA-4797,  Lactobacillus plantarum  PTA-4799,  Lactobacillus salivarius  PTA-4800,  Lactobacillus paracasei  PTA-4798,  Bifidobacterium lactis  PTA-4802, and  Bifidobacterium bifidum  PTA-4801. 
     
     
       5. The bacterial composition according to  claim 1 , comprising from 10 5  to 10 11  CFU of bactena/g of composition. 
     
     
       6. The bacterial composition according to  claim 5 , comprising from 10 8  to 10 11  CFU of bactenalg of composition. 
     
     
       7. A process for the prevention or the reduction of inflammatory bowel disease, comprising the step of administering to a human or an animal an efficient preventing or reducing amount of inflammatory bowel disease, of a bacterial composition as defined in  claim 1 . 
     
     
       8. A process for maintaining the homeostatis of the immune system comprising the step of administering to a human or an animal an efficient maintaining amount of the homeostasis of the immune system, of a bacterial composition as defined in  claim 1 . 
     
     
       9. A process for the prevention or the reduction of allergenicity comprising the step of administering to a human or an animal an efficient preventing or reducing amount of allergenicity, of a bacterial composition as defined in  claim 1 . 
     
     
       10. An immunoadjuvent composition, comprising a bacterial composition as defined in  claim 1 . 
     
     
       11. An immunomodulation method comprising the step of using  Bifidobacterium lactis  PTA-4802. 
     
     
       12. A food, dietary supplement or pharmaceutical composition comprising a composition as defined in  claim 1 . 
     
     
       13. The composition according to  claim 12 , being in the form of a dairy product. 
     
     
       14. The composition according to  claim 13 , being in the form of an infant formula. 
     
     
       15. The composition according to  claim 13 , having immunomodulation properties. 
     
     
       16. A pharmaceutical composition comprising the composition as defined in  claim 1  for the prevention of inflammatory bowel disease. 
     
     
       17. A pharmaceutical composition comprising the composition as defined in  claim 1  for immunomodulation. 
     
     
       18. The immunomodulation method according to  claim 11 , further comprising using at least one additional strain selected from the group consisting of  Lactobacillus acidophilus  PTA-4797,  Lactobacillus plantarum  PTA-4799,  Lactobacillus salivarius  PTA-4800,  Lactobacillus paracasei  PTA-4798, and  Bifidobacterium bifidum  PTA-4801.